Survodutide Research for Type 2 Diabetes
An evidence-based overview of research examining Survodutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=413) demonstrated dose-dependent HbA1c reduction up to 1.71% at 16 weeks, comparable to open-label semaglutide 1mg (1.47%) at matched lower doses. Weight loss reached 8.7%, exceeding semaglutide (5.3%) at higher survodutide doses. NCT07754461 is a named Phase 3 type 2 diabetes registration (recruiting); no results are posted. NCT07768813 is a Phase 1 formulation study (not yet recruiting) and is not a diabetes efficacy trial.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.